UNSPSC 51162609: Benproperine trihydrogen phosphate

This classification denotes an antitussive agent with the molecular formula C21H27NO.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S831Z48C5W, chemically known as 1-(2-(2-benzylphenoxy)-1-methylethyl)piperidine monophosphate, but more generally known as benproperine trihydrogen phosphate, which bears US NIH Compound Identifier 167811. European Medicines Agency schedules benproperine trihydrogen phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05728MIG.

Most nations, for tariff purposes, schedule benproperine trihydrogen phosphate under HS 29333999. SMILES: CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.OP(=O)(O)O.

UNSPSC 51162609 Benproperine trihydrogen phosphate is a Commodity code that in practice captures state and local procurement of pharmaceutical products and drug-related medical supplies rather than the specific chemical compound its name suggests. Recent state and local opportunities under this code show acquisition of naloxone (an opioid antagonist), safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products distributed through established wholesaler networks. Issuing bodies include county health departments and state-administered cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, represent recent active buyers. The scope of work encompasses both direct procurement of specific pharmaceutical units for community health initiatives and supply-chain brokerage through authorized wholesalers serving multiple state and local government facilities across participating jurisdictions.

Geographic activity centers on Florida and Minnesota, with MMCAP's procurement spanning multiple states including Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford; the bid response deadline was July 26, 2023, and bidders were required to provide unit costs, drug-free workplace certification, and E-Verify compliance, with an initial two-year contract term plus optional one-year renewal. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with proposals due March 26, 2026 and contract effectiveness July 1, 2026; vendors must maintain compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, hold two-wholesaler minimum relationships, and accept a 3 percent administrative fee on all contract purchases.